Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
About this item
Full title
Author / Creator
Publisher
New Zealand: Dove Medical Press Limited
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Dove Medical Press Limited
Subjects
More information
Scope and Contents
Contents
Risankizumab, a fully human IgG monoclonal antibody inhibitor of IL-23, is a therapeutic agent currently in late stage development for use in the treatment of moderate-to-severe plaque psoriasis. It is a biologic agent similar to guselkumab and tildrakizumab which targets IL-23 specifically, and has been primarily developed for use in moderate-to-s...
Alternative Titles
Full title
Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_5664af65f7954b83bf51064f2d891fac
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_5664af65f7954b83bf51064f2d891fac
Other Identifiers
ISSN
1177-8881
E-ISSN
1177-8881
DOI
10.2147/DDDT.S167149
